Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019695 · ClinicalTrials.gov registry record · Phase 2
Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00019695: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00019695 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019695, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Ketoconazole may suppress the production of hormones and may interfere in the growth of prostate cancer cells. Alendronate sodium may be effective in preventing bone metastases and bone pain associated with prostate cancer. It is not known if ketoconazole is more effective with or without alendronate sodium. PURPOSE: Randomized phase II trial to study the effectiveness of ketoconazole with or without alendronate sodium in treating patients who have metastatic prostate cancer.
Interventions
- DRUG alendronate sodium
- DRUG ketoconazole
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-03 |
| Est. Completion | 2005-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00019695
The ClinicalTrials.gov registry entry for NCT00019695 describes a study currently listed as terminated, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which alendronate sodium is the first listed.
NCT00019695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00019695 about?
NCT00019695 is a clinical study titled "Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer". RATIONALE: Ketoconazole may suppress the production of hormones and may interfere in the growth of prostate cancer cells. Alendronate sodium may be effective in preventing bone metastases and bone pain associated with prostate cancer. It is not known if ketoconazole is more effective with or without...
What is the current status of trial NCT00019695?
This trial is currently terminated. It is a Phase 2 study. The study started on 1999-03. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00019695?
The interventions under investigation include: alendronate sodium (DRUG), ketoconazole (DRUG).
Who is sponsoring clinical trial NCT00019695?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.